



## Improving Outcomes in Systemic Lupus Erythematosus and Lupus Nephritis

### References

---

- Danila MI, Pons-Estel GJ, Zhang J, et al. [Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort.](#) *Rheumatology* (Oxford). 2009;48:542-545.
- Schur P, Hahn B. Epidemiology and pathogenesis of systemic lupus erythematosus. Pisetsky D, Ramirez-Curtis M (Eds). UpToDate, Waltham, MA. Updated: April 26 2019. Accessed May 30, 2019.
- Chakravarty E, Bush T, Manzi S, Clarke A, Ward M. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. *Arthritis Rheum.* 2007;56:2092-2094.
- Pons-Estel G, Alarcón G, Scofield L, Reinlib L, Cooper G. Understanding the epidemiology and progression of systemic lupus erythematosus. *Semin Arthritis Rheum.* 2010;39:257-268.
- United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018.
- Harley J, Kelly J, Kaufman K. Unraveling the genetics of systemic lupus erythematosus. *Springer Semin Immunopathol.* 2006;28:119-130.
- Wong M, Tsao B. Current topics in human SLE genetics. *Springer Semin Immunopathol.* 2006;28:97-107.
- Costenbader K, Feskanich D, Stampfer M, Karlson E. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. *Arthritis Rheum.* 2007;56:1251-1262.
- Li J, May W, McMurray R. Pituitary hormones and systemic lupus erythematosus. *Arthritis Rheum.* 2005;52:3701-3712.
- Hahn B, Ebling F, Singh R, Singh R, Karpouzas G, La Cava A. Cellular and molecular mechanisms of regulation of autoantibody production in lupus. *Ann N Y Acad Sci.* 2005;1051:433-441.
- Arbuckle M, McClain M, Rubertone M, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. *N Engl J Med.* 2003;349:1526-1533.

Parks C, Cooper G. Occupational exposures and risk of systemic lupus erythematosus: a review of the evidence and exposure assessment methods in population- and clinic-based studies. *Lupus*. 2006;15:728-736.

Cooper G, Dooley M, Treadwell E, St Clair E, Gilkeson G. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. *J Clin Epidemiol*. 2002;55:982-989.

Mok CC, Lau CS. [Pathogenesis of systemic lupus erythematosus](#). *J Clin Pathol*. 2003;56:481-490.

Gladman D. Overview of the clinical manifestations of systemic lupus erythematosus in adults. Pisetsky D, Ramirez-Curtis M (Eds). Waltham, MA. UpToDate. Updated January 8 2018. Accessed May 12, 2019.

Graham K, Utz P. Sources of autoantigens in systemic lupus erythematosus. *Curr Opin Rheumatol*. 2005;17:513-517.

Bertsias G, Cervera R, Boumpas D. Systemic lupus erythematosus: pathogenesis and clinical features. In: Kvien T, Berenbaum F, Bijlsma J, et al., eds. European League Against Rheumatism (EULAR) Textbook on Rheumatic Diseases. 2nd ed London, UK: BMJ; 2015.

Hanly JG, O'Keeffe AG, Su L, et al.: The frequency and outcome of lupus nephritis: results from an international inception cohort study. *Rheumatology (Oxford)* 55: 252–262, 2016

Bagavant H, Deshmukh U, Wang H, et al. Role for nephritogenic T cells in lupus glomerulonephritis: progression to renal failure is accompanied by T cell activation and expansion in regional lymph nodes. *J Immunol*. 2006;177:8258-8265.

Davidson A, Bethunaickan R, Berthier C, Sahu R, Zhang W, Kretzler M. Molecular studies of lupus nephritis kidneys. *Immunol Res*. 2015. Sep 16. [Epub ahead of print]

Bagavant H, Fu S. Pathogenesis of kidney disease in systemic lupus erythematosus. *Curr Opin Rheumatol*. 2009;21:489-494.

Anders H, Weening J. Kidney disease in lupus is not always lupus nephritis. *Arthritis Res Ther*. 2013,15:108.

Song D, Wu L, Wang F, et al. The spectrum of thrombotic microangiopathy in lupus nephritis. *Arthritis Res Ther*. 2013,15:R12.

Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon- $\alpha$  receptor monoclonal antibody, in moderate-to-severe system lupus erythematosus. *Arthritis Rheumatol*. 2017;69:376-386.

Agrawal H, Jacob N, Carreras E, et al. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed strain mice decreases dendritic cell numbers and activation and protects from disease. *J Immunol*. 2009;183:6021-6029.

Liu Z, Davidson A. BAFF inhibition: a new class of drugs for the treatment of autoimmunity. *Exp Cell Res*. 2011;317:1270-1277.

Cancro MP, D'Cruz DP, Khamashta MA. [The role of B lymphocyte stimulator \(BLyS\) in systemic lupus erythematosus](#). *J Clin Invest*. 2009;119:1066-1073.

Xu H, Liu J, Cui X, et al. [Increased frequency of circulating follicular helper T cells in lupus patients is associated with autoantibody production in a CD40L-dependent manner](#). *Cell Immunol*. 2015;295:46-51.

Zhang X, Lindwall E, Gauthier C, et al. [Circulating CXCR5+CD4+ helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production](#). *Lupus*. 2015;24:909-917.

Suarez-Fueyo A, Bradley SJ, Tsokos GC. T cells in systemic lupus erythematosus. *Curr Opin Immunol*. 2016;43:32-38.

Wardemann H, Nussenzweig MC. [B-cell self-tolerance in humans](#). *Adv Immunol*. 2007;95:83-110.

Cappione A, Anolik JH, Pugh-Bernard A, et al. Germinal centre exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. *J Clin Invest*. 2005;115:3205-3216.

American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. [Guidelines for referral and management of systemic lupus erythematosus in adults](#). *Arthritis Rheum*. 1999;42:1785-1796.

Petri M, Orbai AM, Alarcón GS, et al. [Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus](#). *Arthritis Rheum*. 2012;64:2677-2686.

van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, et al. [Treat-to-target in systemic lupus erythematosus: recommendations from an international task force](#). *Ann Rheum Dis*. 2014;73:958-967.

Bertsias G, Ioannidis JP, Boletis J, et al. [EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics](#). *Ann Rheum Dis*. 2008;67:195-205.

Wallace D. Diagnosis and differential diagnosis of systemic lupus erythematosus in adults. Pissetsky D, Ramirez-Curtis M (Eds). UpToDate, Waltham, MA. Accessed October 28, 2015.

Larosa M, Iaccarino L, Gatto M, et al. [Advances in the diagnosis and classification of systemic lupus erythematosus](#). *Expert Rev Clin Immunol*. 2016;12:1309-1320.

Hull R, Goldsmith D. Nephrotic syndrome in adults. *BMJ*. 2008;336:1185-1189.

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for glomerulonephritis. *Kidney Inter Suppl*. 2012;2:139-274.

National Kidney Foundation Kidney Dialysis Outcomes Quality Initiative (NKF-KDOQI). KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. *Am J Kidney Dis*. 2013;62:403-441.

Jennete J, Falk R. Glomerular clinicopathologic syndromes. In: Gilbert S, Weiner D, Gipson D, Perazella M, Tonelli M., eds. National Kidney Foundation. Primer on kidney diseases. 6th ed. Philadelphia, PA: Saunders Elsevier; 2014.

National Kidney Foundation Kidney Dialysis Outcomes Quality Initiative (NKF-KDOQI). KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. *Am J Kidney Dis*. 2002;39:S1-S266.

National Kidney Foundation Kidney Dialysis Outcomes Quality Initiative (NKF-KDOQI). KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. *Am J Kidney Dis*. 2013;62:403-441.

Bruce IN, O'Keefe AG, Farewell V, et al. [Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics \(SLICC\) Inception Cohort](#). *Ann Rheum Dis*. 2015;74:1706-1713.

Urowitz MB, Gladman DD, Ibañez D, et al. [Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort](#). *Arthritis Care Res (Hoboken)*. 2012;64:132-137.

Bomback A, D'Agati V. Kidney manifestations of systemic lupus erythematosus. In: Gilbert S, Weiner D, Gipson D, Perazella M, Tonelli M., eds. National Kidney Foundation. Primer on kidney diseases. 6th ed. Philadelphia, PA: Saunders Elsevier; 2014.

Anders H, Weidenbusch M, Rovin B. Unmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicine. *Clin Kidney J*. 2015;8:492-502.

Manger K, Manger B, Repp R, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. *Ann Rheum Dis*. 2002;61:1065-1070.

Jayne D, Yiu V. Hematuria and proteuinuria. In: Gilbert S, Weiner D, Gipson D, Perazella M, Tonelli M., eds. National Kidney Foundation. Primer on kidney diseases. 6th ed. Philadelphia, PA: Saunders Elsevier; 2014.

Hahn BH, McMahon MA, Wilkinson A, et al. [American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.](#) *Arthritis Care Res* (Hoboken). 2012;64:797-808.

Mosca M, Tani C, Aringer M, et al. [European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies.](#) *Ann Rheum Dis*. 2010;69:1269-1274.

Wallace D. Overview of the management and prognosis of systemic lupus erythematosus in adults. Pissetsky D, Ramirez-Curtis M (Eds). UpToDate, Waltham, MA. Accessed May 12, 2019.

Fanouriakis A, Kostopoulou M, Alunno A, et al. [2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.](#) *Ann Rheum Dis*. 2019;78:736-745.

Wallace D. Overview of the management and prognosis of systemic lupus erythematosus in adults. Pissetsky D, Ramirez-Curtis M (Eds). UpToDate, Waltham, MA. Accessed October 28, 2015.

Mok CC. [Treat-to-target in systemic lupus erythematosus: are we there yet?](#) *Expert Rev Clin Pharmacol*. 2016;9:675-680.

Doria A, Gatto M, Iaccarino L, Punzi L. [Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight.](#) *Lupus*. 2015;24:507-515

Merrill JT, Neuwelt CM, Wallace DJ, et al. [Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.](#) *Arthritis Rheum*. 2010;62:222-233.

Rovin BH, Furie R, Latinis K, et al. [Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.](#) *Arthritis Rheum*. 2012;64:1215-1226.

Merrill J, Buyon J, Furie R, et al. [Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab \(EXPLORER\).](#) *Lupus*. 2011;20:709-716.

Haubitz M. New and emerging treatment approaches to lupus. *Biologics*. 2010;4:263-271.

Murdaca G, Colombo BM, Puppo F. [Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events.](#) *Autoimmun Rev.* 2011;11:56-60.

Wallace DJ, Stohl W, Furie RA, et al. [A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.](#) *Arthritis Rheum.* 2009 Sep 15;61:1168-1178.

Furie R, Petri M, Zamani O, et al; BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum.* 2011;63:3918-3930.

Navarra SV, Guzmán RM, Gallacher AE, et al; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet.* 2011;377: 721-731.

Dooley MA, Houssiau F, Aranow C, et al.; BLISS-52 and -76 Study Groups. [Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.](#) *Lupus.* 2013;22:63-72.

ClinicalTrials.gov. A study of belimumab administered subcutaneously in subjects with systemic lupus erythematosus (SLE) (BLISS-SC phase III) ([NCT01484496](#)). <https://clinicaltrials.gov/ct2/show/NCT01484496?term=bliss-sc+phase+III&rank=1>. Updated November 2017.

U.S. Food and Drug Administration (FDA). Benlysta (belimumab). [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/761043lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761043lbl.pdf). Approved 2011. Updated July 2017.

Falk RJ, Dall'Era M, Appel GB. Clinical features and therapy of lupus membranous nephropathy. UpToDate. [https://www.uptodate.com/contents/clinical-features-and-therapy-of-lupus-membranous-nephropathy?search=lupus%20nephritis&topicRef=3092&source=see\\_link](https://www.uptodate.com/contents/clinical-features-and-therapy-of-lupus-membranous-nephropathy?search=lupus%20nephritis&topicRef=3092&source=see_link). Updated May 18 2018. Accessed June 2 2019.

Alsuwaida A, Husain S, Alghonaim M, et al. [Strategy for second kidney biopsy in patients with lupus nephritis.](#) *Nephrol Dial Transplant.* 2012;27:1472-1478.

Alvarado AS, Malvar A, Lococo B, et al. [The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients.](#) *Lupus.* 2014 Jul;23(8):840-847.

Rovin BH, Parikh SV, Alvarado A. [The kidney biopsy in lupus nephritis: is it still relevant?.](#) *Rheum Dis Clin North Am.* 2014;40:537-552.

De Rosa M, Azzato F, Toblli JE, et al. [A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy.](#) *Kidney Int.* 2018;94:788-794.

Danoff-Burg S, Friedberg F. Unmet needs of patients with systemic lupus erythematosus. *Behav Med.* 2009;35:5-13.

Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. *Arthritis Res Ther.* 2012;14(Suppl 4):S4.

Samuel S, Morgan C, Bitzan M, et al. Substantial practice variation exists in the management of childhood nephrotic syndrome. *Pediatr Nephrol.* 2013;28:2289-2298.

Barbour S, Beaulieu M, Gill J, Reich H, Levin A. Care gaps and barriers to guideline-based management of glomerulonephritis: a survey of nephrologists. Abstract TH-PO1052. American Society of Nephrology (ASN) 2013 Annual Meeting.